Eric Schultz, DO
Allergy & Immunology · West Lake Hills, TXNPI 1578774980
Payments from drug & device makers
Across 468 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$1K
- GSK$1K
- Takeda Pharmaceuticals U.S.A., Inc.$656
- CSL Behring$574
- plus $3K from 29 others
What the payments were for
- Consulting fees$1,64415%
- Food & beverage$8,52180%
- Education$4815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 49 | $2,229 |
| Regeneron Healthcare Solutions, Inc. | 76 | $1,827 |
| AstraZeneca | 40 | $1,259 |
| GSK | 90 | $1,037 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $656 |
| CSL Behring | 25 | $574 |
| Biocryst US Sales Co., LLC | 43 | $500 |
| Octapharma USA, Inc. | 15 | $384 |
| Sanofi-aventis U.S. LLC | 3 | $240 |
| Alk-abello, Inc | 14 | $237 |
| Pharming Healthcare, Inc. | 9 | $215 |
| Genentech USA, Inc. | 7 | $160 |
| Novartis | 7 | $136 |
| Kaleo, Inc. | 6 | $125 |
| Amgen(2 entities) | 6 | $111 |
| Grifols USA, LLC | 5 | $104 |
| ADMA Biomanufacturing LLC | 4 | $97 |
| Lilly USA, LLC | 4 | $93 |
| Ionis Pharmaceuticals, Inc. | 2 | $77 |
| Boehringer Ingelheim | 3 | $74 |
| Incyte Corporation | 3 | $74 |
| Shire North American Group Inc | 3 | $56 |
| Blueprint Medicines Corporation | 2 | $55 |
| Optinose US, Inc. | 3 | $52 |
| Kedrion Biopharma, Inc. | 2 | $48 |
| Hospira, Inc. | 2 | $35 |
| Pfizer | 2 | $31 |
| GC Biopharma USA, Inc. | 1 | $27 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| Phadia US Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Biocryst Pharmaceuticals, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,645 in reported general payments places this provider in the 65th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 58 | $264,626 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 34 | $225,017 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 68 | $215,701 |
| Dupixent PenDupilumab | 11 | $41,162 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $30,929 |
| Epinephrine | 65 | $14,327 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $11,975 |
| DuleraMometasone/Formoterol | 18 | $8,002 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $7,997 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,818 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,935 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,765 |
| Azelastine Hcl | 79 | $2,456 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 11 | $1,783 |
| Montelukast Sodium | 94 | $1,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Cuvitru | $656 | $440,718102 claims |
| CSL BehringHizentra | $574 | $264,62658 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,037 | $46,84074 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $14,32765 claims |
| AstraZenecaBreztri Aerosphere | $1,259 | $6,81811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in West Lake Hills
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
- Barbara BaxterDallas$2.5M
- Lyndon MansfieldEl Paso$2.4M
- Dale MoharKerrville$2.3M
- Erika GonzalezSan Antonio$2.2M
- Richard WassermanDallas$1.9M
- Joseph DiazSan Antonio$1.8M
- Niran AmarWaco$840K
- Robert JacobsSan Antonio$757K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.